WaveWriter Alpha Spinal Cord Stimulator Systems Launches In the U.S.

WaveWriter Alpha Spinal Cord Stimulator Systems were approved by the U.S. Food and Drug Administration in December 2020 and is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs including unilateral or bilateral pain associated with failed back surgery syndrome, Complex Regional Pain Syndrome Types I and II, intractable low back pain and leg pain.

Boston Scientific Signs Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business

SERB, backed by private equity firm Charterhouse Capital Partners since 2017, owns a diversified portfolio of prescription medicines focused on rare and life-threatening diseases.

LOTUS Edge Aortic Valve System Voluntary Recall and Product Discontinuation

The voluntary recall is related solely to the delivery system, as the valve continues to achieve positive and clinically effective performance post-implant. There is no safety issue for patients who currently have an implanted LOTUS Edge valve.

Boston Scientific Launches SpaceOAR Vue Hydrogel: Designed to Create a Temporary Space Between the Prostate & the Rectum

SpaceOAR Vue Hydrogel is a radiopaque version of SpaceOAR Hydrogel that provides the added benefit of enabling the use of computerized tomography scans instead of requiring magnetic resonance imaging.

Ranger Drug-Coated Balloon Receives FDA Approval Reports Boston Scientific

Ranger Drug-Coated Balloon was developed for the treatment of patients with peripheral artery disease in the superficial femoral artery and proximal popliteal artery.

Boston Scientific Launches WaveWriter Alpha ™ Spinal Cord Stimulator Systems In Europe

September 30, 2020 Boston Scientific today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems. The portfolio, consisting of four MRI conditionali, Bluetooth-enabled implantable pulse generators (IPGs), offers expanded personalization based on...

ACURATE neo2 Aortic Valve System Launches in Europe

This next-generation transcatheter aortic valve implantation (TAVI) technology is a new platform designed with a number of features to improve upon the clinical performance of the original ACURATE neo platform.

Boston Scientific Advises CMS Granted a New Technology Add-on Payment for the Eluvia™ Drug-Eluting Vascular Stent System

Boston Scientific notes the NTAP designation, awarded to new medical devices determined to substantially improve the diagnosis or treatment of Medicare beneficiaries, will be effective on October 1, 2020 and will provide eligible hospitals with incremental reimbursement for the Eluvia stent system for up to three years.